Summit Financial Wealth Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$748K Buy
15,600
+534
+4% +$22.9K 0.1% 98
2026
Q1
$554K Sell
15,066
-1,326
-8% -$62.8K 0.08% 107
2025
Q4
$834K Buy
16,392
+7,459
+83% +$381K 0.12% 80
2025
Q3
$529K Buy
8,933
+35
+0.4% +$2.05K 0.08% 100
2025
Q2
$614K Buy
8,898
+173
+2% +$11.8K 0.11% 88
2025
Q1
$606K Sell
8,725
-495
-5% -$40.9K 0.12% 83
2024
Q4
$762K Sell
9,220
-330
-3% -$35.7K 0.15% 74
2024
Q3
$1.14M Sell
9,550
-360
-4% -$48K 0.21% 53
2024
Q2
$1.41M Hold
9,910
0.29% 45
2024
Q1
$1.27M Buy
+9,910
New +$1.18M 0.26% 48
2020
Q4
Sell
-12,000
Closed -$390K 110
2020
Q3
$390K Hold
12,000
0.1% 82
2020
Q2
$395K Hold
12,000
0.11% 88
2020
Q1
$364K Hold
12,000
0.11% 85
2019
Q4
$360K Hold
12,000
0.09% 106
2019
Q3
$307K Hold
12,000
0.08% 118
2019
Q2
$306K Hold
12,000
0.07% 120
2019
Q1
$306K Hold
12,000
0.08% 107
2018
Q4
$276K Sell
12,000
-808
-6% -$18K 0.09% 101
2018
Q3
$270K Buy
+12,808
New +$313K 0.08% 114
2017
Q1
Sell
-12,000
Closed -$215K 145
2016
Q4
$215K Hold
12,000
0.09% 132
2016
Q3
$250K Sell
12,000
-194
-2% -$4.81K 0.11% 122
2016
Q2
$328K Hold
12,194
0.14% 106
2016
Q1
$330K Hold
12,194
0.14% 105
2015
Q4
$354K Buy
+12,194
New +$338K 0.16% 99

Other funds holding NVO

Summit Financial Wealth Advisors's NVO Position: Q2 2026 in Review

Summit Financial Wealth Advisors increased its Novo Nordisk (NVO) stake by 3.5% in Q2 2026, buying an estimated $22.9K and bringing the position to 15,600 shares worth $748K. The position accounts for 0.1% of the portfolio, ranked #98.

Summit Financial Wealth Advisors first reported a position in NVO in Q4 2015 and has held it in 24 quarters since. The position peaked at $1.41M in Q2 2024. 205 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Summit Financial Wealth Advisors held 15,600 shares of Novo Nordisk worth $748K as of Q2 2026.
  • Summit Financial Wealth Advisors bought 534 Novo Nordisk shares in Q2 2026, an estimated $22.9K.
  • Novo Nordisk made up 0.1% of Summit Financial Wealth Advisors's portfolio in Q2 2026, its #98 holding.
  • Summit Financial Wealth Advisors first reported a position in Novo Nordisk in Q4 2015 and has held it in 24 quarters since.
  • Summit Financial Wealth Advisors's Novo Nordisk position peaked at $1.41M in Q2 2024.
  • 205 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Summit Financial Wealth Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.